Format

Send to

Choose Destination
Antiviral Res. 2020 Mar 5;177:104762. doi: 10.1016/j.antiviral.2020.104762. [Epub ahead of print]

Of chloroquine and COVID-19.

Author information

1
Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France. Electronic address: franck.touret@univ-amu.fr.
2
Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France. Electronic address: xavier.de-lamballerie@univ-amu.fr.

Abstract

Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.

KEYWORDS:

2019-nCoV; Antiviral; COVID-19; Chloroquine; SARS-CoV-2

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center